cohort, however, we could not confirm this: high AS expression did not correlate with a higher disease-free survival (Figure 2a) and AS expression did not differ between t(12;21)-positive ALL patients with and without subsequent relapse ( Figure 2b ).
study. This gene is located on chromosome 12p13, a region frequently deleted in leukaemic cells with t(12;21). 4, 5 Deletions on genomic level could interfere with GAPDH expression and thus have effect on asparagine synthetase to GAPDH ratio presented by Stams et al.
In addition, Stams et al present a small but significant difference between the t(12;21) positive and t(12;21) negative untreated ALL samples regarding the percentage of cells in the Sphase. In our original study we reported a decrease of cell percentage in S þ G2/M phases after in vitro L-asparaginase treatment selectively in t(12;21)-positive cells. The observed difference was at the order of one magnitude. The small difference observed by Stams et al in the untreated patient specimens might be of interest, especially when confirmed in an independent cohort. However, there are unanswered issues like why the proportion of G2M phase is not correspondingly depressed and whether this difference might be modulated by the same mechanisms as the L-asparaginase-induced cell cycle arrest. As an explanation for the difference in prognostic relevance of AS expression in our study 1 and Krejci's study, 2 Krejci et al commented that GAPDH as a reference gene might be inappropriate, since this gene is located at 12p13. However, GAPDH is located telomeric from TEL with a distance of approximately 5 Mb. The interstitial deletion of the nontranslocated TEL gene in t(12;21) positive ALL usually encompasses an area centromeric from TEL.
3 Furthermore, GAPDH was equally expressed in t(12;21) positive and t(12;21) negative ALL in a former study. 4 Moreover, no difference in GAPDH expression was found between t(12;21) positive patients with and without a deletion of TEL.
5 Therefore, we believe that GAPDH can be used as a reference gene in RTQ-PCR. Even if we correlate the AS expression of t(12;21) positive ALL patients with clinical outcome, without correcting for GAPDH, opposite results from Krejci et al occur: 5-years pDFS of 27% with high AS expression (expression above the median AS expression (P450)) compared to 5-years pDFS of 94% with low AS expression (Po50); P ¼ 0.002.
The main message of our letter, however, was to extend the findings of Krejci et al concerning the relationship between TEL-AML1 and cell cycle distribution. Our data show that t(12;21) positive ALL already at diagnosis show cell cycle retardation prior to L-Asp treatment. A possible explanation for this is the repression of AML1 target genes by TEL-AML1. 1 Further support of our findings are the fact that TEL-AML1 affects somatic recombination of antigen receptor genes, which is closely related to the cell cycle 6 and the fact that t(12;21) positive ALL have higher AS expression at initial diagnosis compared to t(12;21) negative ALL. 
